Digoxin Shows Promise in Reducing Mortality and Heart Failure Risk in Rheumatic Heart Disease Patients

Recent findings from the Digoxin in Rheumatic Heart Disease (Dig-RHD) trial have highlighted the potential of digoxin to improve outcomes for patients with rheumatic heart disease (RHD). This landmark study, published in a 2025 PubMed article, is the first randomized clinical trial to evaluate digoxin’s impact on clinical outcomes in RHD, a condition that disproportionately affects low- and middle-income countries.

The Dig-RHD Trial: A Breakthrough in RHD Management

Rheumatic heart disease, caused by untreated streptococcal infections, leads to significant morbidity and mortality due to heart failure (HF). Despite its widespread use, digoxin’s efficacy in RHD has not been rigorously tested in large-scale trials until now. The Dig-RHD trial, conducted across 12 academic medical centers in India, enrolled 1,769 symptomatic adult patients with RHD. Participants were randomized to receive either oral digoxin or a placebo, alongside standard care.

The trial’s primary outcome was a composite of all-cause death and new-onset or worsening HF. Key secondary outcomes included HF-related death, hospitalization for HF and quality of life assessments. An interim analysis after half of the primary outcome events occurred found no safety concerns, and the study is expected to conclude its follow-up in December 2025.

Potential Benefits of Digoxin in RHD

Early results from the Dig-RHD trial, reported in a March 2026 social media post by the American College of Cardiology, suggest that digoxin may reduce the risk of death or new-onset/worsening HF compared to placebo. While final results are pending, the trial’s design and preliminary findings underscore the drug’s potential as a cost-effective treatment option for RHD, particularly in resource-limited settings.

Digoxin, an inexpensive cardiac glycoside, has long been used off-label in RHD despite limited evidence of its efficacy. The Dig-RHD trial addresses this gap, providing critical data to inform clinical guidelines and treatment strategies for RHD patients globally.

Implications for Global Health

RHD remains a major public health challenge, particularly in regions with limited access to healthcare. The Dig-RHD trial’s findings could reshape the management of RHD, offering a low-cost, widely available treatment to reduce HF complications and mortality. However, further research is needed to confirm these results and explore long-term benefits and risks.

As the trial concludes, healthcare providers and policymakers will closely monitor its outcomes to determine how best to integrate digoxin into RHD care. The study also highlights the importance of conducting rigorous trials in underrepresented populations to ensure equitable healthcare advancements.

Key Takeaways

• The Dig-RHD trial is the first randomized study to assess digoxin’s impact on RHD outcomes.
• Early results suggest digoxin may reduce the risk of death or worsening heart failure in RHD patients.
• RHD disproportionately affects low- and middle-income countries, where cost-effective treatments are critical.
• Final trial results, expected in late 2025, will provide definitive evidence on digoxin’s role in RHD management.

The Dig-RHD trial represents a significant step forward in addressing the unmet needs of RHD patients. As research continues, the potential of digoxin to improve lives in resource-limited settings remains a promising area of focus for the global health community.